Patents by Inventor Jianming Yu

Jianming Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220016112
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: July 6, 2021
    Publication date: January 20, 2022
    Inventors: Jianming Yu, In Jong Kim, Yat Sun Or
  • Patent number: 11179400
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: November 23, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Jianming Yu, In Jong Kim
  • Patent number: 11091501
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 17, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: In Jong Kim, Jianming Yu, Joseph Panarese, Kevin McGrath, Solymar Negretti-Emmanuelli, Thomas P. Blaisdell, Brian C. Shook, Yat Sun Or
  • Publication number: 20210222488
    Abstract: A winding device for a non-stay-cord venetian blind is disclosed, which comprises a fixing seat, a fixer, winding drums with one-way dampers, a rear cover and iron cores. A non-stay-cord venetian blind adopting the winding device is also disclosed, which comprises a top beam, a bottom beam, slats, cords, a winding device, a motor and a shaft. The winding device adopts a unique separate settlement for the motor, which is convenient for mounting and displacement and easy to roll up and down. During the operation, the non-stay-cord venetian blind keeps horizontal and the bottom beam does not slide down or bounce back in any positions. The winding device is able to be applied on blinds adopt strip or string shaped ladder tape or blinds with center holes, side holes or side slots on the slats. Multiple cords are able to be winded the same winding drum.
    Type: Application
    Filed: August 30, 2017
    Publication date: July 22, 2021
    Inventors: Zhijun Lin, Jianming Yu
  • Patent number: 10975094
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: April 13, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jianming Yu, Solymar Negretti-Emmanuelli, In Jong Kim, Yat Sun Or
  • Patent number: 10906895
    Abstract: The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: February 2, 2021
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: In Jong Kim, Jianming Yu, Thomas P. Blaisdell, Joseph Panarese, Brian C. Shook, Yat Sun Or
  • Patent number: 10881666
    Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: January 5, 2021
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Kai Lin, Michael H. J. Rhodin, Nicole V. McAllister, Yat Sun Or
  • Patent number: 10865215
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: December 15, 2020
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Yat Sun Or
  • Patent number: 10851115
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: December 1, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: In Jong Kim, Joseph Panarese, Thomas P. Blaisdell, Jianming Yu, Brian C. Shook, Yat Sun Or
  • Publication number: 20200323872
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 7, 2020
    Publication date: October 15, 2020
    Inventors: Yat Sun Or, Jianming Yu, In Jong Kim
  • Publication number: 20200299286
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: March 17, 2020
    Publication date: September 24, 2020
    Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
  • Patent number: 10759816
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: September 1, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jianming Yu, Brian C. Shook, Thomas P. Blaisdell, In Jong Kim, Joseph Panarese, Kevin McGrath, Solymar Negretti-Emmanuelli, Yat Sun Or
  • Publication number: 20200223867
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: January 10, 2020
    Publication date: July 16, 2020
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Yat Sun Or
  • Patent number: 10570153
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: February 25, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Yat Sun Or
  • Publication number: 20190315766
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 10, 2019
    Publication date: October 17, 2019
    Inventors: Jianming Yu, Solymar Negretti-Emmanuelli, In Jong Kim, Yat Sun Or
  • Publication number: 20190308964
    Abstract: The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 10, 2019
    Inventors: In Jong Kim, Jianming Yu, Thomas P. Blaisdell, Joseph Panarese, Brian C. Shook, Yat Sun Or
  • Patent number: 10398706
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: These compounds are useful for treating Respiratory Syncytial Virus (RSV) infection. The present invention further relates to pharmaceutical compositions comprising these compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: September 3, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brian C. Shook, In Jong Kim, Jianming Yu, Thomas P. Blaisdell, Joseph Panarese, Yat Sun Or
  • Patent number: 10358441
    Abstract: The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: July 23, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: In Jong Kim, Jianming Yu, Thomas P. Blaisdell, Joseph Panarese, Brian C. Shook, Yat Sun Or
  • Patent number: 10350546
    Abstract: A method for preparing a fungi-bacteria composite microecologics, including: cultivating and conducting high-density fermentations of Zoogloea sp. HJ1 which has been deposited in China Center for Type Culture Collection (CCTCC) with an accession number: CCTCC NO. M2012235, Pandoraea sp. FLX-1 which has been deposited in CCTCC with an accession number: CCTCC NO. M2011242, and Ophiostoma sp. LLC which has been deposited in CCTCC with an accession number CCTCC NO. M2014531 to obtain mixed strains; cultivating, fermenting, and vacuum drying the mixed strains to yield a resulting product which is ground into a powder; cultivating and conducting high-density fermentation of Aspergillus sp. HD-2 which has been deposited in CCTCC with an accession number: CCTCC NO. M2014175 and Trichoderma sp. LW-1 which has been deposited in CCTCC with an accession number: CCTCC NO. M2014176 to yield spores; and mixing the powder and the spores.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: July 16, 2019
    Inventors: Jianmeng Chen, Jiade Wang, Zhuowei Cheng, Jianming Yu
  • Patent number: RE47475
    Abstract: In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of the often chronic, severe and debilitating pain that can accompany inflammatory diseases and neuropathic insults, pain that is often unresponsive to conventional analgesic treatment. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of neuropathic pain, migraine-related pain and inflammatory pain with reduced sedative and ataxic side effects.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: July 2, 2019
    Assignee: WISYS TECHNOLOGY FOUNDATION, INC.
    Inventors: James M. Cook, Shengming Huang, Rahul Edwankar, Ojas A. Namjoshi, Zhi-Jian Wang, Qi Huang, Xiaohui He, Xiaoyan Li, Jianming Yu, Dongmei Han